Loading...
•
Jun 30, 2020
Amneal Q2 2020 Earnings Report
Amneal's financial performance was strong in the second quarter of 2020, with increased revenue and adjusted EBITDA.
Key Takeaways
Amneal Pharmaceuticals reported a net revenue of $465 million for Q2 2020, a 15% increase compared to Q2 2019. The company's GAAP net loss was $(12) million, and adjusted EBITDA was $101 million. Adjusted diluted EPS was $0.13.
Net revenue for Q2 2020 reached $465 million, a 15% increase year-over-year.
GAAP net loss for Q2 2020 was $(12) million; diluted loss per share was $(0.08).
Adjusted EBITDA for Q2 2020 increased by 9% to $101 million.
The company is maintaining its full year 2020 financial outlook.
Amneal
Amneal
Amneal Revenue by Segment
Revenue by Segment
Affordable Medicines Revenue
CapyFin.comSpecialty Revenue
CapyFin.comAvKARE Revenue
CapyFin.com Forward Guidance
Amneal is maintaining its previously provided 2020 guidance.
Revenue & Expenses
Visualization of income flow from segment revenue to net income